title: Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia.
abstract: Tissue factor pathway inhibitor (TFPI) inhibits the extrinsic coagulation system. A major pool of TFPI is associated with the vascular endothelium and can be mobilized into the circulation by heparin. In circulating blood, TFPI is mainly associated with LDL (80%), whereas 10% to 20% is carrier free. In this study, heparin administration caused a 2.2-fold and a 7.5-fold increase in TFPI activity and TFPI antigen, respectively, in 25 patients with phenotypes IIa and IIb hyperbetalipoproteinemia. Because the antigen determination of TFPI almost exclusively measures carrier-free TFPI, more than 90% of the heparin-induced increase in TFPI activity was caused by mobilization of carrier-free TFPI from the vascular endothelium. Therapeutic lowering of total cholesterol (a decrease of 31.1 +/- 11.6%, P < .001) by 40 mg/d lovastatin in 17 patients with hyperbetalipoproteinemia was accompanied by a parallel decrease in TFPI activity (of 27.7 +/- 24.2%, P < .001) because of a reduction in LDL-TFPI complexes. However, drug intervention did not affect carrier-free TFPI or the magnitude of the vascular pool of TFPI that could be mobilized into the circulation by heparin. Moreover, this reduction of LDL-TFPI complexes did not reduce the anticoagulant potency of TFPI in plasma or of the vascular endothelial pool. The results of this study may imply that the anticoagulant potency of TFPI is associated with its carrier-free form in plasma or on the endothelium and that downregulation of LDL affects neither the size nor the anticoagulant potency of the endothelial pool of TFPI.
authors.affiliation: Department of Medicine, University of Tromsø, Norway.
authors.forename: J B
authors.initials: JB
authors.lastname: Hansen
authors.forename: K R
authors.initials: KR
authors.lastname: Huseby
authors.forename: N E
authors.initials: NE
authors.lastname: Huseby
authors.forename: P M
authors.initials: PM
authors.lastname: Sandset
authors.forename: T A
authors.initials: TA
authors.lastname: Hanssen
authors.forename: A
authors.initials: A
authors.lastname: Nordøy
mesh_terms: D000328:Adult; D001777:Blood Coagulation; D015992:Body Mass Index; D002784:Cholesterol / Q000097:blood*; D008078:Cholesterol, LDL / Q000097:blood; D002850:Chromatography, Gel; D004730:Endothelium, Vascular / Q000378:metabolism; D005260:Female; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood* / Q000188:drug therapy; D008074:Lipoproteins / Q000097:blood* / Q000378:metabolism; D008148:Lovastatin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
chemical_list: D008078:Cholesterol, LDL; D008074:Lipoproteins; D014280:Triglycerides; C051928:lipoprotein-associated coagulation inhibitor; D006493:Heparin; D002784:Cholesterol; D008148:Lovastatin